Novartis
Breast Cancer Study Shows Number of Mutated PIK3CA Alleles Affects Tumor Aggressiveness
Studies in breast tumors revealed a "biphasic" relationship between mutant PIK3CA allele dosage and stem cell-like features as well as aggressiveness.
FDA Approves Foundation Medicine's Liquid Biopsy Test as CDx for Novartis' Tabrecta in NSCLC
The blood-based test is the second Foundation Medicine assay approved to ID patients eligible for the drug due to mutations leading to MET exon 14 skipping.
Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases
Using the BRAF-V600 tumor mutation as a marker, investigators identified pre-treatment and on-treatment ties between ctDNA and patient outcomes.
Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project
The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.